Member Info for chillpill1

Whilst the fact is EU and Europe generally needs to produce more metals and oil due the geopolitical situation I worry that the wokesters will hinder projects.

I use the World leading Salamander uranium project as an example.

It’s all about being able to extend patent life via combination therapies. The Keytruda patent expires in 2028 and Merck don’t want to give up $25bn of revenue per year.

Well worth a read on the AR to understand what they do.

https://crimsontide.co.uk/wp-content/uploads/2023/05/Annual-Reports-and-Accounts-2022.pdf

Hopefully it is a hidden gem. Growing at 25-30% per year. P/E of 10 for next years. High margin, low churn rate. Cash of £3m.

Management own a lot, relatively low salaries and have sold businesses before.

It’s all about communication. In this case Ichor just placed an order through a market maker and were prepared to take a price lower than the market.
Often when options expire the Company,seller and company broker will work together to find a buyer to try and reduce market volatility. Often in a more illiquid stock it can be a good opportunity for a new fund to get a position.

Why? With biotech shares this type of volatility is entirely normal. Make sure you only invest what you are prepared to lose.

It is perfectly normal for such volatility in biotech stocks-that is the name of the game. High risk, high reward. Having said that, especially as the news is so good, the company should have a plan on how to deal with blocks of stock such as those from the options. Back in 2021 Lindy found a biotech analyst to take her options at 20p but nothing was done here. Anyway looks like they are probably out now.

My opinion is the Company have leading edge technology but have completely failed in the last few months to expand the shareholder base.
Barely anyone has heard of Scancell let alone know what they do.
In many ways I like the way they prefer to be under the radar but living under a stone isn’t the answer either.
They should not be focusing too much on the retail investors-sorry-although there should be quarterly proactive investor type interviews.
The main focus should be seeing specialist biotech funds and Family offices not only in the UK but US, Switzerland and Singapore. There are plenty of wealthy philanthropists out there who want to back new cancer treatments.
They need to get out there and tell people what they are doing.

Not all 23 patients will of had their 8 week scans imo.

Emptyend,
$24k is just for the terminal itself and as you will know you also have the market access/exchange fees on top so it all adds up quite quickly but yes the base fee doesn’t seem to have changed for 20 years.
Yes the shareholder data came off Bloomberg too although you can pay around £500 to get a detailed share register as a one off from Argus Vickers.

If you ask a broker who uses a Bloomberg terminal (subscription $24k per annum) to look up SCLP news they will confirm there was a scheduled roadshow. It’s not made up!
It’s perfectly normal to see shareholders and potential shareholders after results. Potential new funds generally have to do their own dd and go through investment committees before buying shares.

AB if that is what some thought then they are completely clueless! A 10 or 20% patient response would be amazing considering all patients have had no response to the standard of care treatments.
Better off having uneducated investors out tbh.

Getting a response on 2 ovarian cancer patients including one from the low dosage first cohort far outweighs any news on Covidity.
Covidity is bottom of the list-they wouldn’t have done it if the hadn’t have got the Govt grant.

The biggest news is the response on Ovarian cancer…

I have mentally written off Covidity for some reason. It appears to be bottom of the priority list.

Lindy’s last sale of shares in Nov 21 @ 20p were to a former biotech analyst/fund manager for c. £470k.
You can see it in the share register…if you pay for it.

Agree C7. Previously they were cash constrained. With the promising early data it is looking like recruitment is going to be much faster than planned. Last time I looked I think I saw approx 9 centres recruiting.

Historically SCLP have not be great with timelines. With the trials they are subject to 3rd parties on providing the data.

Much better to leave until next year. Second week of Jan when everyone is back makes sense and hopefully they can report a few more people have joined the Modi trial.

There is no great rush.

I hope Lindy gets to present to plenty of biotech funds in UK and US in next couple of months ahead of greater patient data that should come through in early spring.

Sounds like you are talking about Biogen. They have spent a decade or so trying to convince the FDA their treatment benefits Alzheimer’s patients. All very subject.

With the Modi trial it is much faster and far more objective in its end points.

In the next 3/4 months we will have a very good idea if it likely to be a blockbuster product or not.

I’m expecting just one Modi update between now and Christmas. That will probably include the safety data they have mentioned.

I’m going for some stage next week or the week after.

It’s Q1 next year with more patients enrolled when it could get very exciting.